Recently, glucagon-like peptide 1 (GLP-1) and GLP-1R agonists are widely used for DM treatment although GLP-1 has a half-life of 2 min and undergoes rapid degradation by dipeptidyl peptidase 4 and endopeptidase, although stable forms may prevent this quick degradation. Here, GLP1R is linked to diabetes mellitus.